IDXG - ピ―ディ―アイ (Interpace Diagnostics Group Inc.) ピ―ディ―アイ

 IDXGのチャート


 IDXGの企業情報

symbol IDXG
会社名 Interpace Diagnostics Group Inc (ピ―ディ―アイ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 事業サポ―トサ―ビス   医療関連(Health Care)
概要 事業概要 インターペース・ダイアグノスティックス・グループ(Interpace Diagnostics Group Inc)(旧名:PDI Inc.)はヘルスケア商品化会社である。同社は、米国における医薬品バイオテクノロジー・診断・ヘルスケア企業に市場参入戦略と実行を提供する。同社は、商業サービス及び「Interpace Diagnostics」という2つの事業部門を有する。同社はまた、その「Interpace Diagnostics」部門を通じて、胃腸及び内分泌癌に関連する遺伝的・その他分子変化を検出するための分子診断テストの開発・商品化を行う。同社は、胃腸癌に関連する遺伝的・その他分子変化を検出するために設計された3つの開発後期にある付加的診断テスト、甲状腺癌に関連する分子変化を検出するために設計された1つの開発後期にある診断テストを有する。   ピ―ディ―アイは、米国の製薬、バイオ技術、医療企業に外部委託商業サ―ビスを提供する米国企業。事業は、販売サ―ビス、マ―ケティング・サ―ビス、製品商業化サ―ビスに分かれる。臨床教育サ―ビス、デジタル通信を含むプロモ―ション・サ―ビスのほか、製薬、バイオテクノロジ―、医療機器などの商品化ソリュ―ションを提供する。   Interpace Biosciences, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.
本社所在地 Morris Corporate Center 1 Building C 300 Interpace Parkway Parsippany NJ 07054 USA
代表者氏名 Stephen J. Sullivan スティーブンJ.サリバン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 412-224-6100
設立年月日 31472
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 75人
url www.interpacediagnostics.com
nasdaq_url https://www.nasdaq.com/symbol/idxg
adr_tso
EBITDA EBITDA(百万ドル) -8.07600
終値(lastsale) 1.3234
時価総額(marketcap) 37312303.535
時価総額 時価総額(百万ドル) 38.34421
売上高 売上高(百万ドル) 18.88200
企業価値(EV) 企業価値(EV)(百万ドル) 28.26021
当期純利益 当期純利益(百万ドル) -13.36000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Interpace Diagnostics Group Inc revenues increased 41% to $10.3M. Net loss before extraordinary items increased 14% to $5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Change in fair value of contingent consi decrease from $5.8M (income) to $0K Sales and marketing increase of 52% to $4.1M (expense).

 IDXGのテクニカル分析


 IDXGのニュース

   Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020  2020/06/24 20:20:00 GlobeNewswire
PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial…
   Stock Alert: Interpace Biosciences Stock Up 20% In Premarket  2020/04/27 08:38:00 RTT News
Shares of Interpace Biosciences Inc. (IDXG) are up 20% in pre-market today, after the company announced that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions, a specialty benefit management company with more than 3 million members, focused on laboratory testing.
   Interpace Biosciences CEO Jack Stover On Diagnostics Business: 'Much Of The Growth Opportunity Is Around Awareness'  2020/04/01 20:26:10 Benzinga
Interpace Biosciences (NASDAQ: IDXG ) provides complex molecular analysis for the early diagnosis and treatment of cancer. The company also supports the development of targeted therapeutics. Benzinga interviewed Jack Stover, Interpace's president and CEO, about the business. Benzinga: One of Interpace's business partnerships is with Genecast Biotechnology in China. Can you give some insight into this partnership? Stover: Genecast is associated with our biopharma business. They also provide clinical trial services to Chinese companies looking for drug approval. Interpace will be bringing to them U.S. pharmaceutical companies that need a Chinese clinical component for their trials, while Genecast will be bringing to us Chinese companies that need a U.S. clinical component to their trials. So this is a first step for us in international expansion, along with a few others in Western Europe. Benzinga: What is Interpace's approach to expand in the molecular testing sector? Stover: Our core business is broken into two pieces, both around a molecular diagnostic environment.
   Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners - NetworkNewsWire  2020/01/23 18:45:44 NetworkNewsWire
Leading private equity firms 1315 Capital and Ampersand Capital Partners’ recent investment agreement with Interpace signal a “clear vote of confidence” Company’s business units, Interpace Diagnostics and Interpace Pharma Solutions, support the biotech and pharmaceutical sectors as they seek to improve early cancer diagnosis and promote increasingly effective therapies Life sciences industry forecast to reach … Continue reading "Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners"
   The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug  2019/11/26 13:06:41 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.
   Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020  2020/06/24 20:20:00 GlobeNewswire
PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial…
   Stock Alert: Interpace Biosciences Stock Up 20% In Premarket  2020/04/27 08:38:00 RTT News
Shares of Interpace Biosciences Inc. (IDXG) are up 20% in pre-market today, after the company announced that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions, a specialty benefit management company with more than 3 million members, focused on laboratory testing.
   Interpace Biosciences CEO Jack Stover On Diagnostics Business: 'Much Of The Growth Opportunity Is Around Awareness'  2020/04/01 20:26:10 Benzinga
Interpace Biosciences (NASDAQ: IDXG ) provides complex molecular analysis for the early diagnosis and treatment of cancer. The company also supports the development of targeted therapeutics. Benzinga interviewed Jack Stover, Interpace's president and CEO, about the business. Benzinga: One of Interpace's business partnerships is with Genecast Biotechnology in China. Can you give some insight into this partnership? Stover: Genecast is associated with our biopharma business. They also provide clinical trial services to Chinese companies looking for drug approval. Interpace will be bringing to them U.S. pharmaceutical companies that need a Chinese clinical component for their trials, while Genecast will be bringing to us Chinese companies that need a U.S. clinical component to their trials. So this is a first step for us in international expansion, along with a few others in Western Europe. Benzinga: What is Interpace's approach to expand in the molecular testing sector? Stover: Our core business is broken into two pieces, both around a molecular diagnostic environment.
   Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners - NetworkNewsWire  2020/01/23 18:45:44 NetworkNewsWire
Leading private equity firms 1315 Capital and Ampersand Capital Partners’ recent investment agreement with Interpace signal a “clear vote of confidence” Company’s business units, Interpace Diagnostics and Interpace Pharma Solutions, support the biotech and pharmaceutical sectors as they seek to improve early cancer diagnosis and promote increasingly effective therapies Life sciences industry forecast to reach … Continue reading "Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners"
   The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug  2019/11/26 13:06:41 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.
   Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020  2020/06/24 20:20:00 GlobeNewswire
PARSIPPANY, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial…
   Stock Alert: Interpace Biosciences Stock Up 20% In Premarket  2020/04/27 08:38:00 RTT News
Shares of Interpace Biosciences Inc. (IDXG) are up 20% in pre-market today, after the company announced that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions, a specialty benefit management company with more than 3 million members, focused on laboratory testing.
   Interpace Biosciences CEO Jack Stover On Diagnostics Business: 'Much Of The Growth Opportunity Is Around Awareness'  2020/04/01 20:26:10 Benzinga
Interpace Biosciences (NASDAQ: IDXG ) provides complex molecular analysis for the early diagnosis and treatment of cancer. The company also supports the development of targeted therapeutics. Benzinga interviewed Jack Stover, Interpace's president and CEO, about the business. Benzinga: One of Interpace's business partnerships is with Genecast Biotechnology in China. Can you give some insight into this partnership? Stover: Genecast is associated with our biopharma business. They also provide clinical trial services to Chinese companies looking for drug approval. Interpace will be bringing to them U.S. pharmaceutical companies that need a Chinese clinical component for their trials, while Genecast will be bringing to us Chinese companies that need a U.S. clinical component to their trials. So this is a first step for us in international expansion, along with a few others in Western Europe. Benzinga: What is Interpace's approach to expand in the molecular testing sector? Stover: Our core business is broken into two pieces, both around a molecular diagnostic environment.
   Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners - NetworkNewsWire  2020/01/23 18:45:44 NetworkNewsWire
Leading private equity firms 1315 Capital and Ampersand Capital Partners’ recent investment agreement with Interpace signal a “clear vote of confidence” Company’s business units, Interpace Diagnostics and Interpace Pharma Solutions, support the biotech and pharmaceutical sectors as they seek to improve early cancer diagnosis and promote increasingly effective therapies Life sciences industry forecast to reach … Continue reading "Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners"
   The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug  2019/11/26 13:06:41 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.

 関連キーワード  (事業サポ―トサ―ビス 米国株 ピ―ディ―アイ IDXG Interpace Diagnostics Group Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)